Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application To FDA For Treatment Of Atopic Dermatitis In Adults And Children Ages 6 Years And Older
Portfolio Pulse from Bill Haddad
Arcutis has submitted a Supplemental New Drug Application to the FDA for its Roflumilast Cream 0.15% for the treatment of atopic dermatitis in adults and children aged 6 years and older.
September 12, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis' submission of a new drug application to the FDA could potentially lead to a new revenue stream if approved.
The submission of a new drug application to the FDA is a significant step for Arcutis. If the application is approved, it could potentially open a new revenue stream for the company, which would likely have a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100